Washington, DC (July 9, 2013)—
The Personalized Medicine Coalition (PMC) today announced that Patrick J. Balthrop, president and CEO of Luminex Corporation was elected to the Coalition's board of directors for a three-year term.
"Pat will be a strong addition to the Coalition. As CEO of Luminex, an important player in the field of personalized medicine, his company has been on the forefront of developing innovative products that assist patients, including instruments and assays that make health care faster, more accurate and affordable. His leadership, notably in navigating the regulatory arena, will serve PMC well," said Stafford O’Kelly, former president of Abbott Molecular and current chairman of the PMC.
Mr. Balthrop joined Luminex Corporation as President and CEO in May of 2004. Prior to joining Luminex, Mr. Balthrop was employed by Fisher Scientific International as President of Fisher Healthcare for two years. He spent 20 years in the medical devices and diagnostics divisions at Abbott Laboratories, successfully transforming several businesses and franchises. His product development career achievements include the introduction of the world’s first blood test for HIV and leading the development of the most widely used immunoassay assay testing system.
“I strongly believe personalized medicine has the potential to improve patient care and am honored to serve on the Coalition’s board. I am committed to working with its members on public policy issues to encourage its development,” said Patrick J. Balthrop, president and CEO of Luminex Corporation.
About the Personalized Medicine Coalition:
The Personalized Medicine Coalition (PMC), representing innovators, scientists, patients, providers and payers, promotes the understanding and adoption of personalized medicine concepts, services and products to benefit patients and the health system. For more information about PMC, visit www.personalizedmedicinecoalition.org.